Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 4/29/2008 First Published: 12/16/2005


1.		Phase II/III Randomized Pilot Study of Androgen Suppression (AS) Alone Versus AS in Varying Combinations With Zoledronate, Docetaxel, Prednisolone, and/or Celecoxib in Patients With Locally Advanced or Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				Not specified				Other				MRC-STAMPEDE EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476


2.		Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Prevention				Approved-not yet active				18 to 70				Other				RUN 2008-4198 ABR nr.: NL23569.091.08, CMO: 2008/148, EudraCT: 2008-003696-43, NCT00808743


3.		Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Other				tasmc-05-na-05160-ctil NCT00295035


4.		Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				SLCSG0501 NCT00300729


5.		Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				TASMC-07-NA-132-CTIL NCT00486460


6.		Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				3c-03-19 NCT00159484


7.		A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				NP01/07/03 NCT00212108


8.		Celebrex With Preoperative Chemoradiation - Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UHN REB 02-0130-C Ontario Cancer ResearchNetwork, NCT00188565

Last Modified: 8/30/2006 First Published: 7/23/2006


9.		Phase I/II Study of Celecoxib in Patients With Resectable Head and Neck Squamous Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				CHUV-CEPO-161-05 EU-20627, NCT00357617


10.		Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Prevention				Active				18 and over				Other				0405-2006 NCT00400374

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute